Acute lymphoblastic leukemia (ALL) is a heterogeneous disorder, with the greatest
prevalence in children, but it also affects adults, and has an increasing incidence with age …

The Philadelphia chromosome is the most common cytogenetic abnormality found in adult
patients diagnosed with acute lymphoblastic leukemia. The result of this abnormality is the …

The advent of imatinib, a selective inhibitor of the ABL tyrosine kinase, has revolutionized
the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ …

The prognosis of Philadelphia chromosome-positive (Ph+) and/or BCR-ABL-positive acute
lymphoblastic leukemia (ALL) is extremely poor, and for decades allogeneic hematopoietic …

Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) includes at
least one-quarter of all adults with ALL. Until recently, conventional chemotherapy programs …

Significant advances in the treatment of Philadelephia chromosome (Ph)–or BCR-ABL–
positive acute lymphocytic leukemia (ALL) have been made since the discovery of the …

The clinical management of patients with Philadelphia chromosome-positive (Ph+) acute
lymphoblastic leukemia (ALL) has been challenging primarily due to the aggressive nature …

The tyrosine kinase inhibitor (TKI) imatinib has become an integral part of front-line therapy
for Ph+ ALL, with remission rates exceeding 90% irrespective of whether imatinib is given …

The tyrosine kinase inhibitor (TKI) imatinib has become an integral part of front-line therapy
for Philadelphia chromosome-positive acute lymphoblastic leukaemia, with remission rates …

Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) accounts for
approximately one-fourth of cases of adult ALL. It typically presents with an aggressive …